While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2025.
For fiscal 2025, the company now projects adjusted earnings in a range of $6.55 to $6.85 per share on worldwide total revenues of about $45.5 billion.
On average, 25 analysts polled expect the company to report earnings of $6.92 per share on a revenues decline of 2.59 percent to $46.27 billion for the year. Analysts' estimates typically exclude special items.
The outlook reflects the near-term impact of generics across Revlimid, Pomalyst, Sprycel and Abraxane, which is expected to result in a revenue decline of approximately 18 to 20 percent of the Legacy Portfolio. This is expected to be partially offset by the continued strength of the Growth Portfolio.
This guidance also reflects an approximate $500 million expected negative impact to revenue due to foreign exchange.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.